Q2
KVUE — Q2 2026 Financial Report Analysis
Kenvue grew Q2 2026 sales 3.0% (organic +1.6%), but inflation, tariffs and higher marketing spend held operating income to +1.0%; EPS rose to $0.24 mainly on a lower tax rate, and a July appeals ruling revived federal Tylenol lawsuits ahead of the Kimberly-Clark deal expected to close in Q4.